Adaptimmune Therapeutics plc(ADAP)

Description: Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

---

Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Cancer Immunotherapy Acid Non Small Cell Lung Cancer Melanoma Ovarian Cancer Multiple Myeloma Peptides Virotherapy Small Cell Lung Cancer Sarcoma Hematological Malignancies Esophageal Cancer Oncolytics Biotech Tumors Of The Hematopoietic And Lymphoid Tissues Adoptive Cell Transfer Immunotherapy Products Amino Acids Cancer Immunotherapy Product Breast And Lung Cancer Cell Receptors Synovial Sarcoma

---

Home Page: www.adaptimmune.com

ADAP Technical Analysis

60 Jubilee Avenue
Abingdon, OX14 4RX
United Kingdom
Phone: 44 12 3543 0000

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)